Monday, April 23, 2018 10:23:24 PM
Published on Apr 19, 2017
Dr. David "Dedi" Meiri from the Cancer Research lab at the Technion in Israel (aka "Dedi's Lab") takes us through a fascinating presentation on the identification of the effects of different Cannabis extracts on the proliferation and cell death of various cancer cell lines (and classification) according to genetic profile.
1. I think this is a very interesting presentation that takes a few replays to understand because I am not a scientist or Doctor. However, notice Dr. Meiri is looking for a specific cannabinoid to combat the illness based on the research he started 2 years ago.
2. They are now able to take an extract and identify the cannabinoids and 20 different strains that can be prescribed to the patient. Dr. Mieri mentions that each strain is a different medicine. There is a specifity between what is in the cannabis and what is affecting the cells being treated.
3. 96 different treatments are being analyzed by Israeli researchers and it is very important that the right type of cannabis is used to combat different illnesses due to the different effectiveness of each strain of cannabinoids. There is at least 144 different cannabinoids .
4. They are noticing that there is variability in the effectiveness of different cannabis types grown in different greenhouses at different times.
Connections to BLDV
5. Notice at 5:50 in the June 1, 2017 interview how the BLDV CEO refers to grow operations being set up in Florida and how they are high tech. The CEO explains that in the MMJ industry they are more concerned with the exact complement of cannabinoids in the plant. Josh indicates it is more of a recipe relying on genetics and monitoring of controllable factors within controlled spaces.
BLDV's environmental control knowledge through their work with Zeno Controls and Verve Living Systems gave them the position to understand the total environment of the space. Josh indicates that in the MMJ industry, it is important to bring technology to different areas. Connect the dots!
BLDV has tried to highlight the significant and strategic benefits of importing Israeli technologies for North American application in the following subsequent PRs and interviews:
6. 9/26/17 PR - Blue Diamond Ventures Inc. launches Israeli Operation to Develop Standards: http://www.otcmarkets.com/ajax/showNewsReleaseDocumentById.pdf?id=27510
7. 10/19/17 PR - Blue Diamond Ventures Inc., Cannabis Clean Update: https://www.otcmarkets.com/ajax/showNewsReleaseDocumentById.pdf?id=27825
8. 12/5/17 PR - Blue Diamond Consulting LLC secures rights to Oricann® Cannabis Lighting:
https://www.otcmarkets.com/ajax/showNewsReleaseDocumentById.pdf?id=28580
9. 12/21/17 PR - BLDV Acquires 25% of Cann10 North America Holdings Ltd. :
https://globenewswire.com/news-release/2017/12/21/1269006/0/en/BLDV-Acquires-25-of-Cann10-North-America-Holdings-Ltd.html
10. 12/4/17 BLDV CEO Interview:
11. Jan ’18 update – BLDV CEO Interview:
- I think as pharmaceutical companies introduce different cannabis extracts and doctors start prescribing different MMJ targeted to treat specific illnesses, they will require reliable cultivators that can control grow and environmental factors to ensure the right cannabinoids are provided in the right MMJ strain as part of a secure and safe MMJ supply on a consistent basis.
- Hence, this is why I think BLDV's approach to partner with Israeli firms to secure multiple opportunities to bring Medical Cannabis products and technology to North America where AMS will implement the correct high tech cultivation methods as part of the integrated facility approach is timely and full of foresight of the future MMJ market. See further information provided in these two posts:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=132672130
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=132701804
- Although this YT clip is from last year's CannaTech, I find it fascinating at how far ahead Israel is in researching medical cannabis technologies and which cannabinoids are effective to fight diseases. I think this presentation gives some good context on the role that Cann10’s Israeli technologies can have in supporting BLDV's science based approach through the bridge that they can provide to the BioCannacuetical on the road to Biopharmaceutical cannaceutical as mentioned in the 4/9/18 PR:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=140117417
- Note that Dr. David Meiri is a member of scientific committee for the CannX 2018 – The 3rd International Medical Cannabis Conference being organized by Cann10 in Tel Aviv on 14-16 October 2018: https://cannx.org/2018/about-cannx/committee#.Wty4CTGWzIU
Go BLDV!
Buy cautiously and sell reluctantly. All of my posts are In My Opinion only based on the DD I have completed. Please do your own DD and make your own decisions.
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM